Should I continue low-dose aspirin after placement of a Watchman left atrial appendage closure device?

Aspirin Use After Watchman Device Implantation

Yes, aspirin should be continued long-term after Watchman device placement, but the initial post-procedural antithrombotic regimen has evolved significantly from the original trial protocols, with contemporary evidence supporting simplified approaches that reduce bleeding risk while maintaining stroke prevention.

Standard Post-Procedural Antithrombotic Protocol

The FDA-approved protocol from pivotal trials specified a structured approach 1:

• First 45 days: Warfarin (target INR 2.0-3.0) plus aspirin
• 45 days to 6 months: Dual antiplatelet therapy (aspirin plus clopidogrel) if adequate LAA closure confirmed on imaging
• Beyond 6 months: Aspirin monotherapy indefinitely 1

However, this protocol is rarely followed in contemporary practice, with only 12.2% of patients receiving the full FDA-approved regimen 2.

Contemporary Evidence-Based Approaches

Simplified Anticoagulation Strategies

Real-world data demonstrates that simplified regimens without aspirin during the initial period may actually be superior 2:

• Warfarin alone or DOAC alone (without aspirin) showed significantly lower risk of adverse events at 45 days compared to warfarin plus aspirin (HR 0.692 and 0.731 respectively) 2
• The benefit of anticoagulation without aspirin persisted through 6-month follow-up 2
• This challenges the original trial protocol and suggests aspirin may increase bleeding without additional thrombotic protection during the anticoagulation phase 2

Single Antiplatelet Therapy

For patients with absolute contraindications to anticoagulation 3, 4:

• Aspirin monotherapy (typically 100 mg daily) can be used from implantation, though this represents off-label use 3, 4
• Duration of 6 months or less showed comparable outcomes to longer therapy in selected patients 3, 4
• Thromboembolic event rates were 2.7 per 100 patient-years, representing a 73% reduction from predicted rates 4
• Major bleeding occurred in 3.6 per 100 patient-years 4

Dual Antiplatelet Therapy

DAPT (aspirin plus clopidogrel) was used in 60% of patients in the EWOLUTION registry 3:

• No significant difference in ischemic endpoints compared to other strategies 3
• May represent a middle-ground approach for patients unable to take anticoagulation 3

Long-Term Aspirin Continuation

After the initial post-procedural period (typically 6 months), aspirin monotherapy should be continued indefinitely 1:

• This recommendation stems from the original trial design where aspirin alone was used after documented device endothelialization 1
• The 2024 ESC guidelines note that observational studies support antiplatelet therapy without increased device-related thrombosis or stroke 5
• However, the optimal long-term regimen remains an area of ongoing investigation 5, 6

Critical Considerations and Pitfalls

Device-Related Thrombus Risk

• Occurs in 1.7-7.2% of patients and increases stroke risk 5
• Can be detected as late as 1 year post-implantation, mandating surveillance imaging 5
• The initial 45-day period is highest risk for both bleeding and thrombotic complications 1

Patient Selection Matters

A major paradox exists: patients with bleeding contraindications to anticoagulation (the ideal candidates for LAAO) still require post-procedural antithrombotic therapy that carries bleeding risk 5:

• The pivotal trials excluded patients with firm contraindications to anticoagulation 1
• Real-world registries show successful outcomes with antiplatelet-only strategies in these high-risk patients 7, 3, 4
• For patients with prior intracranial hemorrhage, short-term anticoagulation (45 days) followed by DAPT then aspirin alone appears safe 7

Bleeding Risk Monitoring

• Combined warfarin with antiplatelet therapy significantly increases bleeding risk and requires close monitoring 8, 9, 10, 1
• Hypertension control is essential as it reduces both ICH and ischemic stroke risk in anticoagulated patients 1

Practical Algorithm

For patients suitable for anticoagulation:

1. Use warfarin or DOAC alone (without aspirin) for 45 days post-implant 2
2. Perform TEE at 45 days to confirm adequate LAA closure 1
3. If adequate closure: transition to aspirin 81 mg daily indefinitely 1
4. If residual leak: continue anticoagulation or consider DAPT 11

For patients with contraindications to anticoagulation:

1. Use aspirin 81-100 mg daily from implantation 3, 4
2. Consider adding clopidogrel for first 1-6 months 3
3. Continue aspirin indefinitely 3, 4

Ongoing surveillance:

• TEE or cardiac CT at 45 days and 6-12 months to detect device-related thrombus 5
• Annual clinical follow-up indefinitely 5